Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials

Brodalumab, a fully human anti‐interleukin‐17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate‐to‐severe psoriasis.

[1]  M. Song,et al.  Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial , 2018, The British journal of dermatology.

[2]  G. Girolomoni,et al.  The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  M. Lebwohl,et al.  Rapid onset of action in patients with moderate‐to‐severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE‐2 and AMAGINE‐3) , 2017, Journal of the American Academy of Dermatology.

[4]  A. Gottlieb,et al.  A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[5]  L. Rudnicka,et al.  Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases , 2016, Postepy dermatologii i alergologii.

[6]  B. Strober,et al.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.

[7]  J. Gudjonsson,et al.  Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation , 2013, The Journal of Immunology.

[8]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[9]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.